Neurocrine Biosciences, Inc. (BVMF:N1BI34)
Brazil
· Delayed Price · Currency is BRL 42.04
+1.48 (3.65%)
At close: Dec 5, 2025
Neurocrine Biosciences Revenue
Neurocrine Biosciences had revenue of $794.90M USD in the quarter ending September 30, 2025, with 27.78% growth. This brings the company's revenue in the last twelve months to $2.68B, up 19.61% year-over-year. In the year 2024, Neurocrine Biosciences had annual revenue of $2.36B with 24.81% growth.
Revenue (ttm)
$2.68B
Revenue Growth
+19.61%
P/S Ratio
5.87
Revenue / Employee
$1.49M
Employees
1,800
Market Cap
83.92B BRL
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.36B | 468.20M | 24.81% |
| Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
| Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
| Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
| Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rede D'Or São Luiz | 54.20B |
| Raia Drogasil | 42.23B |
| Hypera | 6.97B |
| Fleury | 8.07B |
| Odontoprev | 2.53B |
| Diagnósticos da América | 12.57B |
| Empreendimentos Pague Menos | 14.27B |
| Blau Farmacêutica | 1.77B |